These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 33227175

  • 1. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.
    Kvien TK, Conaghan PG, Gossec L, Strand V, Østergaard M, Poddubnyy D, Williams N, Porter B, Shete A, Gilloteau I, Deodhar A.
    Arthritis Care Res (Hoboken); 2022 May; 74(5):759-767. PubMed ID: 33227175
    [Abstract] [Full Text] [Related]

  • 2. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
    Deodhar AA, Dougados M, Baeten DL, Cheng-Chung Wei J, Geusens P, Readie A, Richards HB, Martin R, Porter B.
    Arthritis Rheumatol; 2016 Dec; 68(12):2901-2910. PubMed ID: 27390130
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Pricop L, Andersson M, Readie A, Porter B.
    Arthritis Res Ther; 2017 Dec 22; 19(1):285. PubMed ID: 29273067
    [Abstract] [Full Text] [Related]

  • 4. Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
    Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B, Measure 2 Study Group.
    Arthritis Care Res (Hoboken); 2017 Jul 22; 69(7):1020-1029. PubMed ID: 28235249
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
    Wei JC, Baeten D, Sieper J, Deodhar A, Bhosekar V, Martin R, Porter B.
    Int J Rheum Dis; 2017 May 22; 20(5):589-596. PubMed ID: 28544533
    [Abstract] [Full Text] [Related]

  • 6. Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study.
    Deodhar A, Conaghan PG, Kvien TK, Strand V, Sherif B, Porter B, Jugl SM, Gandhi KK, MEASURE 2 study group.
    Clin Exp Rheumatol; 2019 May 22; 37(2):260-269. PubMed ID: 30148436
    [Abstract] [Full Text] [Related]

  • 7. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
    Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, Andersson M, Porter B, Richards HB, MEASURE 2 Study Group.
    Ann Rheum Dis; 2017 Mar 22; 76(3):571-592. PubMed ID: 27582421
    [Abstract] [Full Text] [Related]

  • 8. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
    Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A.
    RMD Open; 2019 Mar 22; 5(2):e001005. PubMed ID: 31565244
    [Abstract] [Full Text] [Related]

  • 9. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.
    Pavelka K, Kivitz AJ, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Wang Y, Porter BO, Stefanska A, Richards HB, Rohrer S, MEASURE 3 study group.
    ACR Open Rheumatol; 2020 Feb 22; 2(2):119-127. PubMed ID: 31957970
    [Abstract] [Full Text] [Related]

  • 10. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
    Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, MEASURE 1 Study Group, MEASURE 2 Study Group.
    N Engl J Med; 2015 Dec 24; 373(26):2534-48. PubMed ID: 26699169
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).
    Baraliakos X, Østergaard M, Gensler LS, Poddubnyy D, Lee EY, Kiltz U, Martin R, Sawata H, Readie A, Porter B, SURPASS Study Group.
    Clin Drug Investig; 2020 Mar 24; 40(3):269-278. PubMed ID: 31983056
    [Abstract] [Full Text] [Related]

  • 12. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.
    Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Delicha EM, Rohrer S, Richards H.
    RMD Open; 2017 Mar 24; 3(2):e000592. PubMed ID: 29435364
    [Abstract] [Full Text] [Related]

  • 13. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
    Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W.
    Lancet; 2013 Nov 23; 382(9906):1705-13. PubMed ID: 24035250
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).
    Kishimoto M, Taniguchi A, Fujishige A, Kaneko S, Haemmerle S, Porter BO, Kobayashi S.
    Mod Rheumatol; 2020 Jan 23; 30(1):132-140. PubMed ID: 30334633
    [Abstract] [Full Text] [Related]

  • 15. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.
    Huang F, Sun F, Wan WG, Wu LJ, Dong LL, Zhang X, Kim TH, Sengupta R, Šenolt L, Wang Y, Qiu HM, Porter B, Haemmerle S.
    Chin Med J (Engl); 2020 Nov 05; 133(21):2521-2531. PubMed ID: 32925287
    [Abstract] [Full Text] [Related]

  • 16. Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis.
    Navarro-Compán V, Baraliakos X, Magrey M, Östör A, Saffore CD, Mittal M, Song IH, Ganz F, Stigler J, Deodhar A.
    Rheumatol Ther; 2023 Jun 05; 10(3):679-691. PubMed ID: 36820984
    [Abstract] [Full Text] [Related]

  • 17. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T.
    Arthritis Res Ther; 2019 May 02; 21(1):111. PubMed ID: 31046809
    [Abstract] [Full Text] [Related]

  • 18. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
    Braun J, Baraliakos X, Deodhar A, Poddubnyy D, Emery P, Delicha EM, Talloczy Z, Porter B.
    Rheumatology (Oxford); 2019 May 01; 58(5):859-868. PubMed ID: 30590813
    [Abstract] [Full Text] [Related]

  • 19. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study.
    Baraliakos X, Borah B, Braun J, Baeten D, Laurent D, Sieper J, Emery P, McInnes IB, van Laar JM, Wordsworth P, Wollenhaupt J, Kellner H, Colin L, Vandenhende F, Radford K, Hueber W.
    Ann Rheum Dis; 2016 Feb 01; 75(2):408-12. PubMed ID: 26248638
    [Abstract] [Full Text] [Related]

  • 20. Secukinumab: A Review in Ankylosing Spondylitis.
    Blair HA.
    Drugs; 2019 Mar 01; 79(4):433-443. PubMed ID: 30793255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.